Back to User profile » Mrs Esther Garcia Gil
Papers published by Mrs Esther Garcia Gil:
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study
Koopman M, Franssen FME, Gaffron S, Watz H, Troosters T, Garcia-Aymerich J, Paggiaro P, Molins E, Moya M, van Burk L, Maier D, Garcia Gil E, Wouters EFM, Vanfleteren LEGW, Spruit MA
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:517-533
Published Date: 8 March 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial
Wise RA, Chapman KR, Scirica BM, Daoud SZ, Lythgoe D, Garcia-Gil E
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:689-699
Published Date: 18 March 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
Sethi S, Kerwin E, Watz H, Ferguson GT, Mroz RM, Segarra R, Molins E, Jarreta D, Garcia Gil E
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:667-682
Published Date: 22 March 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
D'Urzo AD, Singh D, Donohue JF, Kerwin EM, Ribera A, Molins E, Chuecos F, Jarreta D, Garcia Gil E
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:479-491
Published Date: 26 February 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Evaluation of the psychometric properties of the Early Morning Symptoms of COPD Instrument (EMSCI)
Hareendran A, Make BJ, Zaiser E, Garcia Gil E
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1633-1645
Published Date: 18 May 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:2545-2558
Published Date: 24 August 2017
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
Beier J, Mroz R, Kirsten AM, Chuecos F, Garcia Gil E
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1731-1740
Published Date: 14 June 2017
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
Miravitlles M, Chapman KR, Chuecos F, Ribera A, Garcia Gil E
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:2041-2053
Published Date: 29 August 2016